Neurocrine Biosciences, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Neurocrine Biosciences, Inc. (NBIX) is a neuroscience-focused biopharmaceutical company that discovers, develops and commercializes pharmaceutical products for neurological, neuroendocrine and neuropsychiatric disorders. Founded in 1992 and headquartered in San Diego, California, the company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor approved for tardive dyskinesia in adults and chorea associated with Huntington's disease; ONGENTYS (opicapone), a catechol-O-methyltransferase inhibitor licensed for Parkinson's disease; and partnered products including ORILISSA (elagolix) and ORIAHNN for endometriosis and uterine fibroids. Its pipeline features NBI-1117568, a muscarinic receptor agonist in Phase II for schizophrenia; osavampator (formerly NBI-1065845), an AMPA positive allosteric modulator for major depressive disorder; and preclinical NLRP3 inhibitors for neuroinflammation and immunology; the company operates primarily in the United States with global partnerships. Recent developments include a January 2025 amendment to its collaboration with Takeda, granting Neurocrine exclusive worldwide rights (except Japan) to osavampator following positive End-of-Phase 2 FDA feedback; a November 2025 global licensing agreement with Pharmaron (up to $881.5 million) and collaboration with TransThera Sciences for NLRP3 inhibitors outside Greater China; and strong third-quarter 2025 financial results with INGREZZA net sales of $687 million.
NVIDIA & 2 Best Earnings Growth Stocks to Buy for 2H 2026
Can Neurocrine (NBIX) Run Higher on Rising Earnings Estimates?
3 Reasons Why Growth Investors Shouldn't Overlook Neurocrine (NBIX)
Neurocrine Shares Hit Highs on Sales Spike, Strong Pipeline
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results
Why Crinetics Stock Soared 99% This Week
Neurocrine (NBIX) Upgraded to Strong Buy: What Does It Mean for the Stock?
Reasons Why Investors Should Consider Betting on Neurocrine Stock
Neurocrine Biosciences: Why I Am Upholding A Buy Rating After M&A Deal For Soleno
Neurocrine Biosciences Initiates Phase 2 Study of Crinecerfont in Pediatric Patients Under 4 Years Old with Classic Congenital Adrenal Hyperplasia
Neurocrine Biosciences (NBIX) Is Up 6.46% in One Week: What You Should Know
5 Relative Price Strength Stocks to Buy for the Second Half
Is Neurocrine (NBIX) a Solid Growth Stock? 3 Reasons to Think "Yes"
Best Momentum Stocks to Buy for June 24th
New Strong Buy Stocks for June 24th
Best Value Stocks to Buy for June 24th
Soleno Therapeutics Presents New VYKAT® XR (diazoxide choline) Data at ENDO 2026 Demonstrating Meaningful and Durable Improvements in Hyperphagia and Behavioral Symptoms in Prader-Willi Syndrome Following Randomized Withdrawal Period
Neurocrine Biosciences Presents First Retrospective Case Series of CRENESSITY® (crinecerfont) in Patients with Classic Congenital Adrenal Hyperplasia Due to 11β‑Hydroxylase Deficiency at ENDO 2026
Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improved Growth Measures in Pediatric Patients with Classic Congenital Adrenal Hyperplasia at ENDO 2026
Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improvements in Cardiometabolic Outcomes in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2026